| DHR_3c2e658a | by the end of 2026 | 2026-10-01 | 2026-12-31 | Completion of StatLab acquisition by Leica Biosystems, subject to customary closing conditions and regulatory approvals. | This acquisition is expected to strengthen Leica Biosystems' value proposition by integrating consumables, instruments, automation, and digital pathology, supporting Danaher's integrated delivery network strategy. It is also anticipated to be accretive to adjusted EPS in the first full year of ownership and grow high single digits over the long term. | Ticker | 2026-07-21 | earnings_transcript | DHR (ticker) |
| DIM.PA_3c26cef8 | by year-end | 2026-10-01 | 2026-12-31 | Receipt of the outstanding EUR 9 million in U.S. tariff refunds. | The receipt of these funds will improve cash flow and net profit, reinforcing the company's financial discipline and balance sheet strength. | Ticker | 2026-10-22 | earnings_transcript | DIM.PA (ticker) |
| DIM.PA_b8977381 | at year-end | 2026-10-01 | 2026-12-31 | Sartorius Group's net debt to underlying EBITDA ratio is expected to decrease to slightly above 3x. | This target demonstrates the company's continued financial discipline and deleveraging progress, reinforcing its commitment to an investment-grade rating and potentially improving financial flexibility. | Ticker | 2026-02-03 | earnings_transcript | DIM.PA (ticker) |
| RGEN_d5d97e45 | Q4 2026 | 2026-10-01 | 2026-12-31 | Continued strong performance in China, with greater than 40% revenue growth in Q3 and robust orders, expected to continue through Q4 2026. | China is identified as the fastest-growing biopharmaceutical market, and sustained strong growth in this region is crucial for Repligen's overall revenue and strategic expansion in Asia Pacific. | Ticker | 2026-10-27 | earnings_transcript | RGEN (ticker) |
| RGEN_c080b60a | Q4 2026 | 2026-10-01 | 2026-12-31 | Realization of initial operating expense synergies from BioLife acquisition, including capturing public company and certain leadership costs. | These completed actions represent more than half of the anticipated Year 1 synergies and are expected to be accretive to operating margin, contributing to the $0.05 EPS accretion target for 2027. | Ticker | 2026-10-27 | earnings_transcript | RGEN (ticker) |
| GLW_8d0284b0 | on December 1st | 2026-12-01 | 2026-12-01 | Corning's management presentation at the UBS Global Technology and AI Conference. | This event provides an opportunity for management to update investors on strategic initiatives, market conditions, and future outlook, potentially influencing investor sentiment and stock performance. | Ticker | 2026-10-27 | earnings_transcript | GLW (ticker) |
| AVTR_5d6352c4 | Tuesday, December 8, in New York City | 2026-12-08 | 2026-12-08 | Avantor to host its Investor Day in New York City. | This event will provide a comprehensive overview of the business strategy, financial objectives, and an opportunity for investors to engage with the leadership team, potentially including updates on portfolio optimization. | Ticker | 2026-07-29 | earnings_transcript | AVTR (ticker) |
| AVTR_27f9bec9 | December 8 | 2026-12-08 | 2026-12-08 | Avantor Investor Day. | Management will provide a deeper look at segments, strategy, capital allocation, and a long-term financial framework, outlining a roadmap for value creation, which is crucial for investor understanding and future outlook. | Ticker | 2026-10-28 | earnings_transcript | AVTR (ticker) |
| DHR_89fff5b5 | in January | 2027-01-01 | 2027-01-31 | Danaher to provide a more quantitative and detailed guidance outlook for fiscal year 2027. | This event will provide investors with a clearer financial roadmap and expectations for the upcoming fiscal year, which could significantly impact investor sentiment and valuation. | Ticker | 2026-10-21 | earnings_transcript | DHR (ticker) |
| DIM.PA_3d37009d | in the beginning of 2027 | 2027-01-01 | 2027-03-31 | Full formalization and implementation of the new 'One Sartorius' operating model with new Executive Board responsibilities. | This aims to improve customer experience, drive clear accountabilities, strengthen product development, and enhance operational excellence, supporting future growth. | Ticker | 2026-10-22 | earnings_transcript | DIM.PA (ticker) |
| DIM.PA_8a362e1b | as of Q1 2027 | 2027-01-01 | 2027-03-31 | Mandatory implementation of the new IFRS 18 financial reporting standard. | This will change the face of the P&L by dividing it into operating, investing, and financing parts, increasing transparency around alternative performance measures and simplifying modeling for analysts. | Ticker | 2026-10-22 | earnings_transcript | DIM.PA (ticker) |
| RGEN_1ab1efe8 | by the beginning of next year | 2027-01-01 | 2027-03-31 | OEM partnership in China becomes operational for local manufacturing of filters. | This initiative is expected to increase Repligen's competitiveness and access to the local Chinese market, a significant growth region, and is part of a strategy to regain market share. | Ticker | 2026-07-28 | earnings_transcript | RGEN (ticker) |
| DIM.PA_6f77aabb | on February 23 | 2027-02-23 | 2027-02-23 | Publication of 2026 full year results, including pro forma figures for 2025 and 2026 under the new segment reporting structure, and 2027 guidance based on the new structure. | This provides transparency and preparation time for investors and analysts, simplifying modeling by aligning segment reporting with the corporate structure and mirroring Sartorius Stedim Biotech's financials. | Ticker | 2026-10-22 | earnings_transcript | DIM.PA (ticker) |
| DIM.PA_ad244d90 | in March | 2027-03-01 | 2027-03-31 | Sartorius Capital Markets Day to provide more detailed insights on market analysis and strategy. | This event will offer deeper strategic considerations and market analysis, potentially clarifying the company's long-term outlook and growth drivers, which could influence investor sentiment. | Ticker | 2026-02-03 | earnings_transcript | DIM.PA (ticker) |